Biocon gains as EU approves pertuzumab biosimilar, its fifth oncology biosimilar in US and EU
Upstox · · AI-summarised by FinFlash
Biocon shares rose 1.08% to an early high of Rs 363.30 after the European Commission granted marketing approval for Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer. Biocon said it is the first biosimilar authorised under the EMA's new tailored clinical approach, and CEO Shreehas Tambe said it is the company's fifth oncology biosimilar approved in both Europe and the United States. The stock is down 6.4% this year.
So What?
EU approval broadens Biocon's oncology biosimilar revenue pipeline and supports the stock after a weak year. Watch launch timing and pricing in European markets.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.